Abstract
Background In the general population, illness after infection with the SARS-CoV-2 Omicron variant is less severe compared with previous variants. Data on the disease burden of Omicron in immunocompromised patients are lacking. We investigated the clinical characteristics and outcome of a cohort of immunocompromised patients with COVID-19 caused by Omicron.
Methods Solid organ transplant recipients, patients on anti-CD20 therapy, and allogenic hematopoietic stem cell transplantation recipients on immunosuppressive therapy infected with the Omicron variant, were included. Patients were contacted regularly until symptom resolution. Clinical characteristics of consenting patients were collected through their electronic patient files. To identify possible risk factors for hospitalization, a univariate logistic analysis was performed.
Results A total of 114 consecutive immunocompromised patients were enrolled. Eighty-nine percent had previously received three mRNA vaccinations. While only one patient died, 23 (20%) required hospital admission for a median of 11 days. A low SARS-CoV-2 IgG antibody response (<300 BAU/mL) at diagnosis, higher age, being a lung transplant recipient, more comorbidities and a higher frailty were associated with hospital admission (all p<0.01). At the end of follow-up, 25% had still not fully recovered. Of the 23 hospitalized patients, 70% had a negative and 92% a low IgG (<300 BAU/mL) antibody response at admission. Sotrovimab was administered to 17 of them, of which one died.
Conclusions While the mortality in immunocompromised patients infected with Omicron was low, hospital admission was frequent and the duration of symptoms often prolonged. Besides vaccination, other interventions are needed to limit the morbidity from COVID-19 in immunocompromised patients.
Summary COVID-19-associated morbidity and mortality in immunocompromised patients is unknown for the SARS-CoV-2 Omicron variant. This prospective registry, demonstrated low COVID-19-associated mortality in these vulnerable patients. However, morbidity remained substantial. Other interventions to abate COVID-19 severity are needed.
Competing Interest Statement
BJAR served at advisory boards of Roche and AstraZeneca. RASH and OCM served once at the advisory board of AstraZeneca. VASHD received grants from ZonMw, Horizon 2020 and Takeda for funding studies, and received payment from Takeda, Pharming, GlaxoSmithKline and CSL Behring for lectures. MMLK served once at the advisory board of Takeda. All other authors declare no competing interests.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The institutional review board at Erasmus MC University Medical Center in Rotterdam (officially called "Medisch Ethische Toetsingscommissie Erasmus MC, METC Erasmus MC") reviewed the protocol. They confirmed that this study does not fall under the Dutch law on research in human subjects (WMO) and therefore waived the requirement for ethical approval of this study. However, all solid organ transplant recipients provided written informed consent for the use of their clinical data as part of an ongoing quality improvement program and the non-solid organ transplant group consented for use of their data in the context of this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵# contributed equally to this manuscript
Alternate author S. Reshwan K. Malahe, Department of Internal Medicine and Erasmus MC Transplant Institute, Erasmus MC University Medical Center, Rotterdam, The Netherlands, Tel. 0031 624362337, Mail: s.malahe{at}erasmusmc.nl
I edited the abstract that I had to enter on medxriv (thus not the abstract in the manuscript itself). Last time I forgot to make the subheadings bold (so the abstract looks a bit messy right now), so I did this now. I also deleted the attached eps file, as the graph was already present in the manuscript itself.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
